Focus Partners Wealth Has $19.67 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• Focus Partners Wealth increased its holdings in IDEXX Laboratories, Inc. by 15.4% in the first quarter, now owning approximately 0.06% of the company, valued at $19.67 million.
• IDEXX reported quarterly earnings of $3.63 per share, exceeding analyst estimates, and had revenue of $1.11 billion, marking a 10.6% increase year-over-year.
• Insider transactions were notable, with executives selling significant shares recently; a total of 54,057 shares worth about $34.3 million were sold over the past ninety days.

Focus Partners Wealth increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 15.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,831 shares of the company's stock after purchasing an additional 6,255 shares during the period. Focus Partners Wealth owned approximately 0.06% of IDEXX Laboratories worth $19,667,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. Balyasny Asset Management L.P. raised its position in IDEXX Laboratories by 230.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 2,455 shares of the company's stock worth $1,015,000 after purchasing an additional 1,712 shares in the last quarter. Lazard Asset Management LLC raised its position in IDEXX Laboratories by 4.5% in the fourth quarter. Lazard Asset Management LLC now owns 7,777 shares of the company's stock worth $3,214,000 after purchasing an additional 338 shares in the last quarter. OMERS ADMINISTRATION Corp raised its position in IDEXX Laboratories by 6.0% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 6,880 shares of the company's stock worth $2,844,000 after purchasing an additional 389 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in IDEXX Laboratories in the fourth quarter worth about $317,000. Finally, Nomura Holdings Inc. raised its position in IDEXX Laboratories by 24.4% in the fourth quarter. Nomura Holdings Inc. now owns 6,335 shares of the company's stock worth $2,619,000 after purchasing an additional 1,241 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $645.16 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The company has a 50 day moving average price of $601.69 and a 200 day moving average price of $512.04. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The stock has a market capitalization of $51.62 billion, a PE ratio of 53.72, a price-to-earnings-growth ratio of 4.13 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the previous year, the company posted $2.44 EPS. IDEXX Laboratories's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the transaction, the executive vice president owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director directly owned 262 shares of the company's stock, valued at $169,600.46. This represents a 89.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock worth $34,293,468 over the last ninety days. 0.98% of the stock is currently owned by insiders.

Analyst Ratings Changes

IDXX has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Leerink Partners lifted their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. BTIG Research lifted their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Piper Sandler reiterated a "neutral" rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Finally, Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research note on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.